SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lipsky PE, van der Heijde DM, St Clair EW, Furst D, Breedveld F, Kalden JR, et al, and the Anti-tumour necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 2
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 41826.
  • 3
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 2519.
  • 4
    Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003; 62: 11958.
  • 5
    Burmester GR, Monteagudo, Saez I, Malaise MG, Canas da Silva J, Webber DG, et al. Adalimumab (humira®) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice: 12-week outcomes in the ReAct trial. Ann Rheum Dis 2005; 64: S0047.
  • 6
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 7
    WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis: guidelines for prescribing TNF-α blockers in adults with RA. London: British Society for Rheumatology. June 2001.
  • 8
    Prevoo ML, van 't Hof M, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 9
    Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 2004; 63: 13446.
  • 10
    Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. C-Reactive protein as a predictor of infliximab outcome in patients with rheumatoid arthritis: defining subtypes of non-response and subsequent response to etanercept. Arthritis Rheum 2005; 50: 428.
  • 11
    Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 107781.
  • 12
    Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy [letter]. Ann Rheum Dis 2004; 63: 896.
  • 13
    Bingham CO, Haraoui PB, Rigby WF, Montalvo-Lugo V, Chon Y, Eickenhorst T. Disease characteristics of patients with rheumatoid arthritis that failed to respond to infliximab and the response to etanercept therapy: preliminary data from the EMBARK Study [abstract]. Ann Rheum Dis 2005; 64 Suppl 3: S172.
  • 14
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, and the REFLEX trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 15
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 111423.
  • 16
    Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumour necrosis factor-α blockade. Arthritis Rheum 2004; 50: 7258.
  • 17
    Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al, and the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 70210.